Total Payments
$770,575
2024 Payments
$62,203
Companies
27
Transactions
425
Medicare Patients
3,765
Medicare Billing
$80,213
Payment Breakdown by Category
Consulting$695,087 (90.2%)
Research$37,203 (4.8%)
Travel$30,195 (3.9%)
Food & Beverage$7,761 (1.0%)
Other$330.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $695,087 | 261 | 90.2% |
| Unspecified | $37,203 | 9 | 4.8% |
| Travel and Lodging | $30,195 | 50 | 3.9% |
| Food and Beverage | $7,761 | 104 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $330.00 | 1 | 0.0% |
Payments by Type
General
$733,372
416 transactions
Research
$37,203
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim International GmbH | $267,713 | 88 | $0 (2022) |
| Abbott Laboratories | $135,058 | 207 | $0 (2024) |
| CVRx, Inc. | $81,502 | 20 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $59,876 | 6 | $0 (2024) |
| Boehringer Ingelheim RCV GmbH & Co KG | $58,625 | 21 | $0 (2018) |
| ABBVIE INC. | $55,489 | 36 | $0 (2024) |
| AstraZeneca UK Limited | $44,840 | 2 | $0 (2024) |
| Sensible Medical Innovations Ltd | $17,757 | 1 | $0 (2018) |
| PFIZER INC. | $12,517 | 5 | $0 (2020) |
| Respicardia, Inc. | $11,130 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62,203 | 18 | AstraZeneca UK Limited ($44,840) |
| 2023 | $43,637 | 17 | AstraZeneca Pharmaceuticals LP ($24,971) |
| 2022 | $65,851 | 9 | AstraZeneca Pharmaceuticals LP ($32,489) |
| 2021 | $80,530 | 18 | Boehringer Ingelheim International GmbH ($58,710) |
| 2020 | $232,930 | 67 | Boehringer Ingelheim International GmbH ($205,295) |
| 2019 | $73,218 | 106 | Abbott Laboratories ($49,977) |
| 2018 | $135,151 | 114 | Abbott Laboratories ($55,410) |
| 2017 | $77,055 | 76 | Boehringer Ingelheim RCV GmbH & Co KG ($32,900) |
All Payment Transactions
425 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $131.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $12,082.50 | General |
| 10/29/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $121.70 | General |
| Category: Heart Failure | ||||||
| 10/01/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $1,443.75 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 09/17/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $26.44 | General |
| Category: NEUROLOGY | ||||||
| 09/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/21/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $32,757.00 | General |
| 08/21/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $91.80 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 06/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/28/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: NEUROLOGY | ||||||
| 04/18/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $102.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/06/2024 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $35.49 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $1,522.50 | General |
| Category: IMMUNOLOGY | ||||||
| 03/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,416.50 | General |
| 02/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| Category: IMMUNOLOGY | ||||||
| 01/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $2,940.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.98 | General |
| Category: NEUROLOGY | ||||||
| 11/09/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,416.50 | General |
| 11/07/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.53 | General |
| Category: NEUROLOGY | ||||||
| 10/10/2023 | IBSA Pharma Inc. | LICART (Drug), TIROSINT, TIROSINT | Food and Beverage | Cash or cash equivalent | $17.79 | General |
| Category: non-opioid analgesic | ||||||
| 10/07/2023 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $42.76 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/05/2023 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $120.00 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/19/2023 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $1,155.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SMILE Sensible medical innovations lung fluid status monitor allows reducing readmission rate of hearth failure patients | Sensible Medical Innovations Ltd | $17,757 | 1 |
| TAFAMIDIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,540 | 3 |
| M13-545 | AbbVie, Inc. | $4,250 | 1 |
| M13-538 | AbbVie, Inc. | $2,338 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 149 | 153 | $13,224 | $3,430 |
| 2022 | 3 | 237 | 261 | $21,706 | $5,405 |
| 2021 | 10 | 1,038 | 1,223 | $106,876 | $24,629 |
| 2020 | 13 | 2,341 | 3,425 | $210,862 | $46,750 |
Total Patients
3,765
Total Services
5,062
Medicare Billing
$80,213
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 25 | $6,350 | $1,841 | 29.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 18 | $3,024 | $888.54 | 29.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 110 | 110 | $3,850 | $700.39 | 18.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 41 | 55 | $9,240 | $2,495 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 19 | 24 | $6,096 | $1,751 | 28.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 177 | 182 | $6,370 | $1,159 | 18.2% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 730 | 861 | $30,135 | $5,648 | 18.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 65 | 83 | $13,944 | $4,733 | 33.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 57 | 90 | $15,120 | $4,695 | 31.1% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 33 | 33 | $19,008 | $3,125 | 16.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $9,062 | $2,692 | 29.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 32 | $8,128 | $1,764 | 21.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 11 | 11 | $2,849 | $866.80 | 30.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 55 | 55 | $4,125 | $611.72 | 14.8% |
| 93016 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring and physician supervision | Facility | 2021 | 12 | 12 | $1,380 | $206.64 | 15.0% |
| 93790 | Ambulatory blood pressure monitoring, 24 hours or longer, review with interpretation and report | Facility | 2021 | 11 | 11 | $1,925 | $148.90 | 7.7% |
| 93018 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report | Facility | 2021 | 12 | 12 | $1,200 | $137.76 | 11.5% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 1,609 | 2,558 | $89,530 | $17,451 | 19.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 105 | 143 | $24,024 | $6,606 | 27.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 64 | 82 | $20,828 | $6,151 | 29.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 35 | 35 | $13,790 | $4,014 | 29.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 53 | 80 | $13,440 | $2,793 | 20.8% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 199 | 204 | $15,300 | $2,394 | 15.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 12 | 13 | $4,472 | $1,478 | 33.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 23 | $4,163 | $1,293 | 31.1% |
About Dr. Alan Miller, M.D
Dr. Alan Miller, M.D is a Internal Medicine healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518934827.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Miller, M.D has received a total of $770,575 in payments from pharmaceutical and medical device companies, with $62,203 received in 2024. These payments were reported across 425 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($695,087).
As a Medicare-enrolled provider, Miller has provided services to 3,765 Medicare beneficiaries, totaling 5,062 services with total Medicare billing of $80,213. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease
- Location Jacksonville, FL
- Active Since 03/06/2006
- Last Updated 02/22/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1518934827
Products in Payments
- JARDIANCE (Drug) $267,238
- CardioMEMS HF System (Device) $133,859
- Barostim Neo System (Device) $81,502
- PRADAXA (Drug) $58,625
- RINVOQ (Biological) $32,926
- ReDS system (Device) $17,757
- OFEV (Drug) $16,799
- remede System (Device) $11,130
- Optimizer (Device) $7,352
- VYNDAQEL (Drug) $5,870
- EVUSHELD (Drug) $4,296
- Non-Covered $1,050
- TRADJENTA (Drug) $475.00
- ENTRESTO (Drug) $187.59
- Impella (Device) $167.48
- CARDIOMEMS (Device) $121.70
- FFRct (Device) $114.16
- VERQUVO (Drug) $102.00
- VYEPTI (Biological) $95.49
- Inpefa (Drug) $91.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Jacksonville
Siddharth Wayangankar, Md, MD
Internal Medicine — Payments: $1.3M
Internal Medicine $1.3M
Kalina Sanders, M.d, M.D
Internal Medicine — Payments: $626,907
Internal Medicine $626,907
Jose Soto Soto, Md, MD
Internal Medicine — Payments: $576,809
Internal Medicine $576,809
Dr. Jennifer Fulton, Md, MD
Internal Medicine — Payments: $556,016
Internal Medicine $556,016
Dr. Francis Farraye, M.d, M.D
Internal Medicine — Payments: $504,399
Internal Medicine $504,399
Dr. Eddy Gutierrez, Md, MD
Internal Medicine — Payments: $296,024
Internal Medicine $296,024